Global Health (Medanta) Reports Strong FY26 Performance with 19.6% Revenue Growth

Revenue: Rs 4,508.9 crore
PAT: Rs 554.1 crore

Reader Takeaway: Strong revenue and PAT growth driven by volume and capacity expansion, with significant pipeline for future growth.

What just happened

Global Health Limited, operating under the Medanta brand, announced its financial results for the fiscal year 2025-26. Consolidated total income surged by 19.6% year-on-year to Rs 4,508.9 crore. Profit After Tax (PAT) saw a healthy increase of 15.1% to Rs 554.1 crore. The company also reported strong operational performance, with a 15.1% rise in PAT and an EBITDA margin of 23.4% on an EBITDA of Rs 1,056 crore (before ESOP expenses).

Why this matters

These results demonstrate Medanta's robust growth trajectory, driven by both increased patient volumes and strategic capacity expansion. The successful commissioning of the Noida hospital and the extensive pipeline suggest continued momentum and potential for future market share gains. The dividend recommendation also signals confidence in the company's financial health.

The backstory

Medanta has been focused on expanding its operational footprint and service offerings. The commissioning of the 550-bed Noida hospital in November 2025 was a significant event, contributing to the revenue growth in its first year of operation. The company has consistently worked on improving operational efficiency, as seen in the reduced Average Length of Stay (ALOS).

What changes now

The company is set to accelerate its expansion through a robust pipeline of greenfield projects and a strategic acquisition. The Indore cancer hospital acquisition is expected to bolster its oncology services. Shareholders can anticipate further capacity additions in the coming years, which could drive future revenue streams.

Risks to watch

Key risks include the ramp-up and utilization of new facilities, particularly the Noida hospital, and the timely execution of the extensive greenfield project pipeline. Intense competition in the healthcare sector and regulatory changes also pose potential challenges.

Peer comparison

While specific peer results for FY26 are not detailed here, Medanta's growth in revenue and PAT, along with its aggressive expansion, places it among the leading healthcare providers in India. Competitors would likely include Apollo Hospitals, Fortis Healthcare, and Max Healthcare, all of which are also expanding their networks.

Context metrics (time-bound)

• FY 2025-26 Total Income: Rs 4,508.9 crore (+19.6% YoY)
• FY 2025-26 PAT: Rs 554.1 crore (+15.1% YoY)
• FY 2025-26 EBITDA: Rs 1,056 crore (Margin: 23.4%)
• In-patient volume: +16.0% YoY
• Out-patient encounters: +18.7% YoY
• Total operational bed capacity: 3,665 (+20.5% YoY)
• Medanta Noida operational since Nov 2025
• FY25-26 Dividend recommended: Rs 0.50 per equity share

What to track next

Investors should closely monitor the performance and occupancy rates of the new Noida hospital, progress on the greenfield expansion projects, and the successful integration of the Indore cancer hospital acquisition. Updates on patient volumes and ARPOB will also be crucial indicators.